| Ident. | Authors (with country if any) | Title |
|---|
| 000013 (2013) |
Micha Levi [États-Unis] ; Susan Grange [États-Unis] ; Nicolas Frey [Suisse] | Exposure‐Exposure Relationship of Tocilizumab, an Anti–IL‐6 Receptor Monoclonal Antibody, in a Large Population of Patients With Rheumatoid Arthritis |
| 000021 (2010) |
Nicolas Frey [Suisse] ; Susan Grange [Suisse] ; Thasia Woodworth [Royaume-Uni] | Population Pharmacokinetic Analysis of Tocilizumab in Patients With Rheumatoid Arthritis |
| 000022 (2011) |
Leonid Gibiansky [États-Unis] ; Nicolas Frey [États-Unis] | Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach |
| 000025 (2014) |
Shuji Ohta [Japon] ; Tomomi Tsuru [Japon] ; Kimio Terao [Japon] ; Seiji Mogi [Japon] ; Midori Suzaki [Japon] ; Eisuke Shono [Japon] ; Yoshimasa Ishida [Japon] ; Eriko Tarumi [Japon] ; Masato Imai [Japon] | Mechanism‐based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study) |
| 000031 (2005) |
Shumpei Yokota [Japon] ; Takako Miyamae [Japon] ; Tomoyuki Imagawa [Japon] ; Shigeki Katakura [Japon] ; Rumiko Kurosawa [Japon] ; Masaaki Mori [Japon] | Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis |
| 000039 (2011) |
Toshio Tanaka [Japon] ; Keisuke Hagihara [Japon] ; Yoshihito Shima [Japon] ; Masashi Narazaki [Japon] ; Atsushi Ogata [Japon] ; Atsushi Kumanogoh [Japon] | Tocilizumab, a humanized anti‐interleukin‐6 receptor antibody, for the treatment of autoimmune disorders |
| 000043 (2009) |
Kazuko Matsumoto [Japon] ; Takao Nagashima [Japon] ; Shino Takatori [Japon] ; Yuta Kawahara [Japon] ; Masaki Yagi [Japon] ; Masahiro Iwamoto [Japon] ; Hitoaki Okazaki [Japon] ; Seiji Minota [Japon] | Glucocorticoid and cyclosporine refractory adult onset Still’s disease successfully treated with tocilizumab |
| 000113 (2005) |
Josef S. Smolen [Autriche] ; Kurt Redlich [Autriche] ; Jochen Zwerina [Autriche] ; Daniel Aletaha [Autriche] ; Günter Steiner [Autriche] ; Georg Schett [Autriche] | Pro-inflammatory cytokines in rheumatoid arthritis |
| 000154 (2011) |
Atsushi Kaneko [Japon] ; Daihei Kida [Japon] ; Kiwamu Saito [Japon] ; Masami Tsukamoto [Japon] ; Tomotaro Sato [Japon] | Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI |
| 000169 (2015) |
Yanli Zhuang [États-Unis] ; Dick E. De Vries [Pays-Bas] ; Zhenhua Xu [États-Unis] ; Stanley J. Marciniak Jr. [États-Unis] ; Dion Chen [États-Unis] ; Francisco Leon [États-Unis] ; Hugh M. Davis [États-Unis] ; Honghui Zhou [États-Unis] | Evaluation of disease‐mediated therapeutic protein–drug interactions between an anti–interleukin‐6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach |
| 000201 (2014) |
Kosmas Kretsos [Royaume-Uni] ; Georg Golor [Allemagne] ; Astrid Jullion [Belgique] ; Matthew Hickling [Royaume-Uni] ; Suzanne Mccabe [Belgique] ; Stevan Shaw [Royaume-Uni] ; Joby Jose [Royaume-Uni] ; Ruth Oliver [Royaume-Uni] | Safety and pharmacokinetics of olokizumab, an anti‐IL‐6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study |
| 000297 (2011) |
A. Schwarting [Allemagne] | Nierenbeteiligung beim systemischen Lupus erythematodes |
| 000420 (2010) |
S. Pankuweit [Allemagne] ; B. Maisch [Allemagne] | Das Herz bei viralen Infektionen |
| 000475 (2013) |
E. Panasyuk [Russie] ; E. Nasonov [Russie] | AB0310 Ra remission rates with tocilizumab therapy (lornet study: multicentre open-label, phase iv study of the quality of the life patient with severe/moderate ra with adding of tocilizumab to disease-modifying antirheumatic drugs therapy) |
| 000568 (2014) |
Koji Chiba [Japon] ; Hiroyuki Yoshitsugu [États-Unis] ; Yuto Kyosaka [Japon] ; Satofumi Iida [Japon] ; Koichiro Yoneyama [Japon] ; Takahiko Tanigawa [Allemagne] ; Takashi Fukushima [Japon] ; Masaki Hiraoka [Japon] | A comprehensive review of the pharmacokinetics of approved therapeutic monoclonal antibodies in Japan: Are Japanese phase I studies still needed? |
| 000576 (2013) |
Marco Bigoni [Italie] ; Paola Sacerdote [Italie] ; Marco Turati [Italie] ; Silvia Franchi [Italie] ; Marta Gandolla [Italie] ; Diego Gaddi [Italie] ; Sarah Moretti [Italie] ; Daniele Munegato [Italie] ; Carlo A. Augusti [Italie] ; Elena Bresciani [Italie] ; Robert J. Omeljaniuk [Canada] ; Vittorio Locatelli [Italie] ; Antonio Torsello [Italie] | Acute and late changes in intraarticular cytokine levels following anterior cruciate ligament injury |
| 000656 (2013) |
Y. Tanaka ; T. Abe ; T. Takeuchi ; A. Yamamoto ; N. Miyasaka [Japon] | AB0587 Safety and efficacy of abatacept(ABA) demonstrated in patients with rheumatoid arthritis(RA); 4-year data from phase III open-label, multicenter, long-term extension trial |
| 000702 (2013) |
A. Ogata [Japon] | FRI0180 The musashi study: Comparison of subcutaneous tocilizumab monotherapy versus intravenous tocilizumab monotherapy: Results from a double-blind, parallel-group, comparative phase III non-inferiority study in japanese patients with rheumatoid arthritis |
| 000727 (2013) |
G. Burmester [Allemagne] ; T. Takeuchi [Japon] ; O. Barbarash [Russie] ; G. Ranganna [Royaume-Uni] ; D. Close [Royaume-Uni] ; A. Godwood [Royaume-Uni] ; D. Saurigny [Royaume-Uni] | FRI0232 Consistent efficacy and safety outcomes between european and japanese subjects with rheumatoid arthritis following treatment with mavrilimumab in the phase 2 earth study |
| 000748 (2012) |
Ariel C. Bulua [États-Unis] ; Douglas B. Mogul [États-Unis] ; Ivona Aksentijevich [États-Unis] ; Harjot Singh [États-Unis] ; David Y. He [États-Unis] ; Larry R. Muenz [États-Unis] ; Michael M. Ward [États-Unis] ; Cheryl H. Yarboro [États-Unis] ; Daniel L. Kastner [États-Unis] ; Richard M. Siegel [États-Unis] ; Keith M. Hull [États-Unis] | Efficacy of etanercept in the tumor necrosis factor receptor–associated periodic syndrome: A prospective, open‐label, dose‐escalation study |
| 000811 (2007) |
Morihiko Ishizaki [Japon] ; Tetsuro Sasada [Japon] ; Akane Kunitomi [Japon] ; Yoshiteru Konaka [Japon] ; Masato Yagita [Japon] ; Shutaro Gunji [Japon] ; Michiyuki Kanai [Japon] ; Norihiro Nishimoto [Japon] ; Arimichi Takabayashi [Japon] | Uneventful splenectomy and cholecystectomy in a patient treated with anti-interleukin-6 receptor antibody therapy |
